Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse
American Journal of Hematology · Wiley · 2026-10-04 · DOI: 10.1002/ajh.70499

Abstract

ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a comprehensive review of chromosomal abnormalities associated with drug sensitivity and resistance in hematological disorders. This work highlights the emergence of alteration‐driven therapy, with certain agents (e.g., tyrosine kinase inhibitors, menin inhibitors, venetoclax) used across entities sharing common molecular lesions, while others remain disease‐specific, such as in Helicobacter pylori –associated lymphomas.

Read at publisher →

Similar articles